DGX
Quest Diagnostics Incorporated
DGX's fundamentals are strong, but it looks expensive: trading at 26x earnings, above its usual 19x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
DGX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
DGX's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
DGX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $102 | -61% |
| Fair | 19x | $192 | -26% |
| Expensive | 22x | $220 | -15% |
| Forward | 22x | $260 | — |
| Current | 26x | $260 | — |
Historical ranges are pointers, not guarantees.
DGX's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 22x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
DGX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
DGX has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
DGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.60 | +16% |
| Q3 2026 | $10.04 | +18% |
| Q2 2026 | $9.42 | +13% |
| Q1 2026 | $9.05 | +14% |
| Q4 2025 | $8.75 | +14% |
| Q3 2025 | $8.52 | +15% |
| Q2 2025 | $8.35 | +13% |
| Q1 2025 | $7.91 | +6.5% |
| Q4 2024 | $7.69 | +2.7% |
DGX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
DGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.1B | +10% |
| Q2 2026 | $3B | +10% |
| Q1 2026 | $2.9B | +9.2% |
| Q4 2025 | $2.8B | +7.1% |
| Q3 2025 | $2.8B | +13% |
| Q2 2025 | $2.8B | +15% |
| Q1 2025 | $2.7B | +12% |
| Q4 2024 | $2.6B | +15% |
DGX's revenue has grown year over year for 11 quarters in a row: $3.1B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.8 points |
| Q2 2026 | 15% | -0.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 14% | 0 points |
| Q3 2025 | 14% | +0.5 points |
| Q2 2025 | 16% | +1 points |
| Q1 2025 | 13% | +0.4 points |
| Q4 2024 | 14% | +2.1 points |
DGX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over DGX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
DGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $445M | +6.2% |
| Q2 2026 | $459M | +5.3% |
| Q1 2026 | $164M | -17% |
| Q4 2025 | $307M | -10% |
| Q3 2025 | $419M | +68% |
| Q2 2025 | $436M | +63% |
| Q1 2025 | $197M | +294% |
| Q4 2024 | $341M | -25% |
DGX still generates free cash flow, though less than at its 2020 peak: $1.4B over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over DGX on cash flow, with more consistent year-over-year improvement.
DGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.9% | -1M shares |
| 3 years | -1.8% | -2M shares |
| 5 years | -10% | -13M shares |
| Available history | -18% | -24M shares |
DGX has 112M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150M |
| Q4 2025 | $300M |
| Q4 2023 | $275M |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $461M |
| Q3 2022 | $374M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over DGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
DGX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 3.1x | Elevated |
DGX's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
DGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.0 | Neutral |
| Stochastic | 89.7 | Overbought |
DGX's weekly RSI is 70 (neutral) and its Stochastic is 90 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
DGX PE vs Healthcare Sector
| Metric | DGX | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | Same PE |
| PE % | 99 | 29 | 70 pts above |
DGX is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
DGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $243.1 | 6.8% above |
| 20 week MA | $235.9 | 10% above |
| 50 week MA | $209.8 | 24% above |
| 100 week MA | $191.5 | 36% above |
| 200 week MA | $165.4 | 57% above |
DGX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
DGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.9 | $120.2 | +13% |
| 2021 | $120.2 | $167.1 | +39% |
| 2022 | $167.1 | $156.3 | -6.4% |
| 2023 | $156.3 | $137.9 | -12% |
| 2024 | $137.9 | $152.6 | +11% |
| 2025 | $152.6 | $175.9 | +15% |
| 2026 YTD | $175.9 | $259.7 | +48% |
DGX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.